1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

ConclusionsTMB-high was associated with higher ORR in pts with select advanced solid tumors treated with pembrolizumab monotherapy. The tail of the PFS curve favored TMB-high. These data suggest that TMB may be predictive of the efficacy of pembrolizumab monotherapy in pts with the tumor types included in KEYNOTE-158.Clinical trial identificationNCT02628067, December 11, 2015.Editorial acknowledgementMelanie Leiby of Merck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.DisclosureA. Marabelle: Research grant / Funding (institution), principal investigator: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, AstraZeneca/MedImmune, Tesaro, Chugai ; Research grant / Funding (institution): MSD; Travel / Accommodation / Expenses: MSD, AstraZeneca, Roche/Genentech, BMS ; Research grant / Funding (institution), rincipal investigator, sponsor Unicancer; ACSE NIVOLUMAB/NCT03012581 : INCa, Ligue contre le Cancer& BMS; Research grant / Funding (institution), principal investigator, sponsor Leon Berard Cancer Center; ISIJX/NCT02977156: Transgene; Research grant / Funding (institution), principal investigator, sponsor Gustave Roussy; NIVIPIT/NCT02857569 : BMS; Research grant / Funding (institution), principal investigator,...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research